CRIS Current Research Information System

PINNA, ANTONIO DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 34.705
AS - Asia 26.590
EU - Europa 20.208
AF - Africa 1.788
SA - Sud America 1.628
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 14
Totale 84.969
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 34.348
VN - Vietnam 8.032
SG - Singapore 7.094
CN - Cina 6.160
GB - Regno Unito 5.611
DE - Germania 2.753
IT - Italia 2.497
SE - Svezia 2.275
HK - Hong Kong 1.636
IN - India 1.509
FR - Francia 1.465
RU - Federazione Russa 1.220
BR - Brasile 1.180
UA - Ucraina 1.180
IE - Irlanda 837
ZA - Sudafrica 567
JP - Giappone 450
NL - Olanda 450
EE - Estonia 427
FI - Finlandia 355
CI - Costa d'Avorio 345
TG - Togo 341
BD - Bangladesh 318
CH - Svizzera 303
KR - Corea 238
SC - Seychelles 234
BG - Bulgaria 214
AR - Argentina 197
CA - Canada 192
JO - Giordania 175
NG - Nigeria 150
PH - Filippine 135
TH - Thailandia 123
BE - Belgio 114
IQ - Iraq 99
MX - Messico 88
AT - Austria 85
EC - Ecuador 85
PL - Polonia 82
ES - Italia 79
ID - Indonesia 79
TR - Turchia 75
PK - Pakistan 71
IR - Iran 61
GR - Grecia 60
SA - Arabia Saudita 57
TW - Taiwan 55
CL - Cile 47
CO - Colombia 39
UZ - Uzbekistan 37
RO - Romania 36
MY - Malesia 33
MA - Marocco 29
AU - Australia 28
LB - Libano 28
HR - Croazia 27
LT - Lituania 25
PE - Perù 24
VE - Venezuela 21
EG - Egitto 20
ET - Etiopia 20
PY - Paraguay 19
DZ - Algeria 16
KE - Kenya 15
NP - Nepal 15
AE - Emirati Arabi Uniti 14
CR - Costa Rica 14
DK - Danimarca 13
JM - Giamaica 13
NO - Norvegia 13
AL - Albania 12
AZ - Azerbaigian 12
CZ - Repubblica Ceca 12
TN - Tunisia 12
UY - Uruguay 12
DO - Repubblica Dominicana 11
OM - Oman 10
IL - Israele 9
MD - Moldavia 9
PS - Palestinian Territory 9
PT - Portogallo 9
KZ - Kazakistan 8
EU - Europa 7
HN - Honduras 7
KH - Cambogia 7
SI - Slovenia 7
SK - Slovacchia (Repubblica Slovacca) 7
SN - Senegal 6
LK - Sri Lanka 5
LV - Lettonia 5
MK - Macedonia 5
NZ - Nuova Zelanda 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AO - Angola 4
BS - Bahamas 4
GE - Georgia 4
GH - Ghana 4
HU - Ungheria 4
KW - Kuwait 4
LY - Libia 4
Totale 84.865
Salva come PNG Salva come JPEG
Città #
Southend 5.014
Singapore 4.819
Fairfield 3.993
Ashburn 3.375
Chandler 2.306
Woodbridge 1.990
Dong Ket 1.785
Houston 1.746
Wilmington 1.728
Seattle 1.605
Ho Chi Minh City 1.568
Hong Kong 1.555
San Jose 1.479
Cambridge 1.427
Santa Clara 1.290
Hanoi 1.278
Princeton 1.203
Ann Arbor 1.053
Dublin 786
Beijing 754
Boardman 680
Jacksonville 660
Nanjing 561
Lauterbourg 559
Westminster 530
Padova 481
Hefei 453
Bologna 449
Los Angeles 422
Tokyo 400
Berlin 367
New York 352
Abidjan 345
Lomé 341
Dallas 335
Helsinki 307
Council Bluffs 275
Jinan 272
Saint Petersburg 268
Bern 256
Shenyang 254
Buffalo 250
San Diego 234
Haiphong 223
Munich 220
Da Nang 217
Sofia 212
Changsha 179
São Paulo 177
Amman 170
Milan 167
Nanchang 167
Hebei 165
Dearborn 164
Seoul 164
Redondo Beach 159
Frankfurt am Main 156
Turin 153
Florence 147
Guangzhou 139
Mülheim 139
Medford 135
Shanghai 127
Tianjin 125
Abeokuta 118
Jiaxing 114
Menlo Park 112
Brussels 110
Delhi 106
Zhengzhou 103
Bremen 100
The Dalles 95
Hangzhou 94
Falls Church 93
Norwalk 93
Phoenix 89
Redmond 86
Johannesburg 83
Hải Dương 82
Redwood City 81
Olalla 78
Des Moines 77
Biên Hòa 74
Toronto 72
Ningbo 69
Can Tho 67
Chicago 66
Rome 66
London 65
Mahé 63
Orem 63
Haikou 60
Lanzhou 60
Falkenstein 59
Yubileyny 56
Fuzhou 55
Montreal 54
Thái Nguyên 52
Vienna 52
Baghdad 50
Totale 56.127
Salva come PNG Salva come JPEG
Nome #
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 518
Hepatobiliary Scintigraphy in the Preoperative Evaluation of Potential Living Liver Donors 501
Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis 400
Two cases of severe autoimmune manifestations following virological response to peginterferon alpha- 2b + ribavirin in liver transplanted patients with recurrence of chronic hepatitis C 340
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 328
A comprehensive analysis on expected years of life lost due to pancreatic cancer 310
Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability Can Optimize Clinical Outcome 302
Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy 289
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 282
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C 279
Hypothermic Oxygenated New Machine Perfusion System in Liver and Kidney Transplantation of Extended Criteria Donors:First Italian Clinical Trial 277
Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array 272
Prognostic criteria for postoperative mortality in 170 patients undergoing major right hepatectomy 270
A new liver transplant priority for patients with hepatocellular carcinoma. 266
Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. 262
Burnout and psychological distress between surgical and non-surgical residents 257
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 256
Antifungal prophylaxis in liver transplant recipients: one size does not fit all 256
Higher number of known pancreatic cancer mutations highlighted by whole-transcripto- me and whole-exome sequencing predicts cli- nical outcome in early stage patients 255
Infections in liver and lung transplant recipients: A national prospective cohort 254
A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. 254
Comprehensive surgical intestinal rescue and transplantation program in adult patients: Bologna experience. 249
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 245
Anticorpi anti-HLA preformati e Trapianto Combinato Rene-Fegato. Caso clinico. 244
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 243
Surgical therapy for hepatolithiasis: a Western experience. 240
Causes of early acute graft failure after liver transplantation: analysis of a 17-year single-centre experience. 239
Combined liver-kidney transplantation: the experience of the University of Bologna and the case of preoperative positive cross-match. 239
Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques. 237
Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations 234
Conventional split liver transplantation for two adult recipients: a recent experience in a single European center 233
Strategies to Restore Adenosine Triphosphate (ATP) Level After More than 20 Hours of Cold Ischemia Time in Human Marginal Kidney Grafts. 233
Multimodal Surgical Approach for Adult Patients With Chronic Intestinal Pseudo-Obstruction: Clinical and Psychosocial Long-term Outcomes 230
A partnership model between high- And low-volume hospitals to improve results in hepatobiliary pancreatic surgery 228
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 228
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 227
A matched pair analysis of multicenter longterm follow-up after split-liver transplantation with extended right grafts 227
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. 225
Bacterial translocation in adult small bowel transplantation 223
A Multicentric Study on Double Kidney Transplantation 223
Abdominal wall transplantation with microsurgical technique 223
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. 222
Long-term endoscopic follow-up in small bowel transplant recipients: single-center series. 222
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 222
DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods 221
Liver as a Source for Thymidine Phosphorylase Replacement in Mitochondrial Neurogastrointestinal Encephalomyopathy 219
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective 219
Combined kidney-liver, heart-liver, and kidney-pancreas transplantations from a single deceased donor. 218
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma 218
Combined liver–dual kidney transplant: Role in expanded donors 216
Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. 215
COMBINED KIDNEY LIVER TRANSPLANTATION: A SINGLE CENTER EXPERIENCE 215
A new liver extracorporeal device (LEONARDO) to treat swine with post-resection acute liver failure 215
An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. 215
Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. 215
Carbapenem-resistant Klebsiella pneumoniae colonization at liver transplantation:a management challenge 215
Associated benign liver tumors in idiopathic granulomatous hepatitis: a case report 214
Blood monitoring of granzyme B and perforin expression after intestinal transplantation: considerations on clinical relevance. 214
Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation? 214
Reliability of imaging techniques in assessing portal venous thrombosis in patients with hepatocellular carcinoma candidates for liver transplantation 214
Acute cellular rejection monitoring after interstinal transplant: utility of serologic markers and zoom videoendoscopy as support of conventional biopsy and clinical findings. 213
Affidabilità della combinazione di angioecografia perfusionale ed altre tecniche di imaging nella valutazione della trombosi portale in pazienti con epatocarcinoma (HCC) candidati al trapianto di fegato 213
Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pre-transplant Radiology 212
Liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical long-term follow-up and pathogenic implications 212
ITA-MNGIE: an Italian regional and national survey for mitochondrial neuro-gastro-intestinal encephalomyopathy. 211
Coping strategies in intestinal transplantation 211
Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation. 210
Combined heart and liver transplantation for familial amyloidotic polyneuropathy. 210
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 210
Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center 210
Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: Towards tailoring of therapeutic strategies? 210
Application of a fluorescent PCR method for molecular diagnosis of posttransplant lymphoproliferative disorders on routine tissue sections. 209
Analysis of risk factors for early hepatic artery thrombosis after liver transplantation. Possible contribution of reperfusion in the early morning. 208
Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. 208
Pre-transplant psoas muscle density as a ready-to-use and low-cost predictor of patient survival after liver transplant 207
Abdominal wall defect repair with biological prosthesis in transplanted patients: single center retrospective analysis and review of the literature 207
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 207
Increase of portal blood oxygenation by artero-venous shunt in diabetic rats 207
Anatomic variations of intrahepatic bile ducts in a European series and meta-analysis of the literature. 206
Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. 205
Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. 205
Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection. 204
Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. 203
Italian experience in adult clinical intestinal and multivisceral transplantation: 6 years later. 203
Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study 202
Trapianto Combinato Rene-Fegato: Esperienza del Policlinico S.Orsola di Bologna 202
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. 202
Prediction of Three-Year Outcome of Renal Transplantation from Optimal Donors versus Expanded Criteria Donors. 202
Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients. 202
Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period. 201
Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era. 200
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 200
Survival after the diagnosis of de novo malignancy in liver transplant recipients 199
Transcatheter Embolization for Giant Splenic Artery Aneurisms: Still an Open Question 198
Combined liver-kidney transplantation-s. Orsola experience: nephrological aspects. 198
Thorough assessment of portal venous thrombosis in patients with HCC allows adequate selection of candidates for liver transplantation 197
Genomic allelotyping for distinction of recurrent and de novo hepatocellular carcinoma after orthotopic liver transplantation 196
Assessment of donor steatosis in liver transplantation: is it possible without liver biopsy? 196
Prognostic significance of tumor doubling time in mass-forming type cholangiocarcinoma. 196
Combined heart-liver transplantation: A single-center experience 196
Totale 23.409
Salva come PNG Salva come JPEG
Categoria #
all - tutte 230.633
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 230.633
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.902 0 0 0 0 0 0 0 0 0 0 0 2.902
2021/20229.997 1.003 403 591 794 955 535 236 630 356 507 2.252 1.735
2022/202310.182 1.139 1.611 579 1.339 621 704 268 551 1.767 241 859 503
2023/20242.442 201 478 121 263 170 507 117 173 83 171 71 87
2024/202510.237 425 1.858 822 764 1.896 521 608 254 123 652 258 2.056
2025/202624.450 2.407 1.967 2.222 1.663 2.735 1.669 2.464 851 4.858 1.988 832 794
Totale 86.288